| ARBUTUS BIOPHARMA |
| Kanada |
| Gesundheit |
| CA03879J1003 / A14XMD |
| I9DN (Frankfurt) / ABUS (NASDAQ) |
| FRA:I9DN, ETR:I9DN, I9DN:GR, NASDAQ:ABUS |
| - |
| https://www.arbutusbio.co.. |
|
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The company's p..
>Volltext.. |
| 774.63 Mio. EUR |
| 698.1 Mio. EUR |
| 12.6 Mio. EUR |
| -26.45 Mio. EUR |
| -36.46 Mio. EUR |
| -0.19 EUR |
| 3.97 Mio. EUR |
| 19.33 Mio. EUR |
| -38.55 Mio. EUR |
| 18.08 |
| 105.56% |
| 47.7% |
| - |
| - |
| - |
| - |
| ARBUTUS |
| 04.03.26 |
|
||||
|
||||
|
||||
|
||||
|